Andrew Dunham

Andrew Dunham is a seasoned executive with extensive experience in research and development within the healthcare and chemical industries. Currently serving as Chief Executive Officer and Chief Technology Officer at Hemanext since October 2021, Andrew previously held significant roles at New Health Sciences, Inc. from January 2015 to September 2023, where responsibilities included setting the vision for research and clinical affairs and developing strategies for product commercialization. Prior to that, Andrew served as Vice President of Research & Development at Baxter Healthcare from April 2007 to July 2014, overseeing a global R&D organization and leading multiple technical departments. Andrew's career includes a strong foundation in research, beginning at Nalco Chemical Company and the University of Colorado Health Sciences Center, complemented by a PhD in Environmental Analytical Chemistry from the University of Colorado Boulder and a BS in Chemistry from Northern Illinois University.